EP1778857A4 - Direct activation of atiii in whole blood and plasma - Google Patents

Direct activation of atiii in whole blood and plasma

Info

Publication number
EP1778857A4
EP1778857A4 EP05769136A EP05769136A EP1778857A4 EP 1778857 A4 EP1778857 A4 EP 1778857A4 EP 05769136 A EP05769136 A EP 05769136A EP 05769136 A EP05769136 A EP 05769136A EP 1778857 A4 EP1778857 A4 EP 1778857A4
Authority
EP
European Patent Office
Prior art keywords
atiii
plasma
whole blood
direct activation
activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05769136A
Other languages
German (de)
French (fr)
Other versions
EP1778857A1 (en
Inventor
David R Elmaleh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of EP1778857A1 publication Critical patent/EP1778857A1/en
Publication of EP1778857A4 publication Critical patent/EP1778857A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G01N2333/8128—Antithrombin III
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
EP05769136A 2004-07-07 2005-07-07 Direct activation of atiii in whole blood and plasma Withdrawn EP1778857A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58604304P 2004-07-07 2004-07-07
PCT/US2005/024046 WO2006014519A1 (en) 2004-07-07 2005-07-07 Direct activation of atiii in whole blood and plasma

Publications (2)

Publication Number Publication Date
EP1778857A1 EP1778857A1 (en) 2007-05-02
EP1778857A4 true EP1778857A4 (en) 2007-09-26

Family

ID=35787415

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05769136A Withdrawn EP1778857A4 (en) 2004-07-07 2005-07-07 Direct activation of atiii in whole blood and plasma

Country Status (6)

Country Link
EP (1) EP1778857A4 (en)
JP (1) JP2008505912A (en)
CN (1) CN101014717A (en)
AU (1) AU2005269887A1 (en)
CA (1) CA2576173A1 (en)
WO (1) WO2006014519A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19836339B4 (en) 1998-08-11 2011-12-22 N.V. Nutricia carbohydrate mix
EP1597978A1 (en) 2004-05-17 2005-11-23 Nutricia N.V. Synergism of GOS and polyfructose
US8252769B2 (en) 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
EP1721611A1 (en) * 2005-04-21 2006-11-15 N.V. Nutricia Nutritional supplement with oligosaccharides for a category of HIV patients
CA2678064A1 (en) * 2007-02-14 2008-08-21 Academic Medical Center, University Of Amsterdam Intraperitoneal administration of antithrombin iii, related compositions and methods
CN101684646B (en) * 2008-09-27 2011-03-23 海洋石油工程股份有限公司 Height-adjustable cushion pier
US20200085849A1 (en) * 2017-05-18 2020-03-19 Elysium Health, Inc. Methods and compositions for improving sleep

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002058638A2 (en) * 2001-01-26 2002-08-01 The General Hospital Corporation Serpin drugs for treatment of hiv infection and method of use thereof
WO2004100973A2 (en) * 2003-05-13 2004-11-25 The General Hospital Corporation Pharmaceutical compositions of antithrombin iii for the treatment of retroviral diseases.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002058638A2 (en) * 2001-01-26 2002-08-01 The General Hospital Corporation Serpin drugs for treatment of hiv infection and method of use thereof
WO2004100973A2 (en) * 2003-05-13 2004-11-25 The General Hospital Corporation Pharmaceutical compositions of antithrombin iii for the treatment of retroviral diseases.

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COOMBE D R ET AL: "LOW ANTICOAGULANT HEPARIN RETAINS ANTI-HIV TYPE 1 ACTIVITY IN VITRO", AIDS RESEARCH AND HUMAN RETROVIRUSES, MARY ANN LIEBERT, US, vol. 11, no. 11, 1995, pages 1393 - 1396, XP009033624, ISSN: 0889-2229 *
GEIBEN-LYNN RALF ET AL: "Purification of a modified form of bovine antithrombin III as an HIV-1 CD8+ T-cell antiviral factor", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 277, no. 44, 1 November 2002 (2002-11-01), pages 42352 - 42357, XP002288481, ISSN: 0021-9258 *
See also references of WO2006014519A1 *

Also Published As

Publication number Publication date
AU2005269887A1 (en) 2006-02-09
CA2576173A1 (en) 2006-02-09
CN101014717A (en) 2007-08-08
WO2006014519A1 (en) 2006-02-09
EP1778857A1 (en) 2007-05-02
JP2008505912A (en) 2008-02-28

Similar Documents

Publication Publication Date Title
ZA200702069B (en) Silver-releasing articles and methods of manufacture
EP1855833A4 (en) Plasmas and methods of using them
IL213843A0 (en) 4-aminotetracyclines and methods of use thereof
EP1718602A4 (en) Therapeutic and carrier molecules
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
IL217157A0 (en) Devices and methods for integrated continuous manufacturing of biological molecules
PL2689767T3 (en) Methods for improving the condition and appearance of skin
EP1803551A4 (en) Sandwich structure and integrated formed article using the same
HK1097859A1 (en) Anti-cd38 human antibodies and uses therefor -cd38
EP1816358A4 (en) Shape of screw and screw part having the same
IL176923A0 (en) Structured materials and methods
EP1765378A4 (en) Agent capable of downregulating an msf-a-dependent hif-1a anduse thereof in cancer treatment
HK1084307A1 (en) Fixture and button
IL181608A0 (en) Cancer combination therapy comprising azd2171 and imatinib
IL180278A0 (en) Fused pyrimidones useful in the treatment and the prevention of cancer
GB0418328D0 (en) Cancer methods and medicaments
IL179497A0 (en) Carboranylporphyrins and uses thereof
EP1778857A4 (en) Direct activation of atiii in whole blood and plasma
IL177435A0 (en) Expression of plasminogen and microplasminogen in duckweed
EP1838288A4 (en) Therapeutic materials and methods
EP1733045A4 (en) Design and therapeutic use of adpase enhanced apyrases
IL180365A0 (en) Carboranylporphyrins and uses thereof
GB0428170D0 (en) Mono and Combination Therapy
HK1097495A1 (en) Can body and can
GB0310403D0 (en) Improvements in and relating to the control of centrifuges

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070206

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20070829

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20071220

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100202